- Home
- LPCN vs NXTC Comparison
LPCN vs NXTC Comparison
Compare LPCN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- NXTC
- Stock Information
- Founded
- LPCN 1997
- NXTC 2015
- Country
- LPCN United States
- NXTC United States
- Employees
- LPCN N/A
- NXTC N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- NXTC Health Care
- Exchange
- LPCN Nasdaq
- NXTC Nasdaq
- Market Cap
- LPCN 16.1M
- NXTC 13.0M
- IPO Year
- LPCN N/A
- NXTC 2019
- Fundamental
- Price
- LPCN $2.99
- NXTC $5.66
- Analyst Decision
- LPCN Strong Buy
- NXTC Strong Buy
- Analyst Count
- LPCN 2
- NXTC 2
- Target Price
- LPCN $9.00
- NXTC $25.50
- AVG Volume (30 Days)
- LPCN 16.6K
- NXTC 13.3K
- Earning Date
- LPCN 11-06-2025
- NXTC 11-06-2025
- Dividend Yield
- LPCN N/A
- NXTC N/A
- EPS Growth
- LPCN N/A
- NXTC N/A
- EPS
- LPCN N/A
- NXTC N/A
- Revenue
- LPCN $4,208,119.00
- NXTC N/A
- Revenue This Year
- LPCN N/A
- NXTC N/A
- Revenue Next Year
- LPCN N/A
- NXTC N/A
- P/E Ratio
- LPCN N/A
- NXTC N/A
- Revenue Growth
- LPCN N/A
- NXTC N/A
- 52 Week Low
- LPCN $2.68
- NXTC $2.69
- 52 Week High
- LPCN $6.17
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- LPCN 50.61
- NXTC 62.52
- Support Level
- LPCN $2.85
- NXTC $5.19
- Resistance Level
- LPCN $3.08
- NXTC $5.90
- Average True Range (ATR)
- LPCN 0.09
- NXTC 0.29
- MACD
- LPCN 0.01
- NXTC 0.07
- Stochastic Oscillator
- LPCN 59.83
- NXTC 78.46
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.